These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23099424)

  • 1. Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.
    De Beaudrap P; Boullé C; Lewden C; Gabillard D; Nacro B; Diagbouga S; Fassinou P; Hien H; Laurent C; Msellati P;
    Pediatr Infect Dis J; 2013 Apr; 32(4):354-60. PubMed ID: 23099424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
    Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
    d'Arminio Monforte A; Sabin CA; Phillips A; Sterne J; May M; Justice A; Dabis F; Grabar S; Ledergerber B; Gill J; Reiss P; Egger M;
    Arch Intern Med; 2005 Feb; 165(4):416-23. PubMed ID: 15738371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
    Podlasin RB; Wiercinska-Drapalo A; Olczak A; Beniowski M; Smiatacz T; Malolepsza E; Juszczyk J; Leszczyszyn-Pynka M; Mach T; Mian M; Knysz B; Horban A
    Infection; 2006 Aug; 34(4):196-200. PubMed ID: 16896577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).
    Guillén S; García San Miguel L; Resino S; Bellón JM; González I; Jiménez de Ory S; Muñoz-Fernández MA; Navarro ML; Gurbindo MD; de José MI; Mellado MJ; Martín-Fontelos P; Gonzalez-Tomé MI; Martinez J; Beceiro J; Roa MA; Ramos JT;
    HIV Med; 2010 Apr; 11(4):245-52. PubMed ID: 20050937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
    AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
    Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
    AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of antiretroviral therapy on opportunistic infections of HIV-infected children in the therapeutic research, education and AIDS training asia pediatric HIV observational database.
    Prasitsuebsai W; Kariminia A; Puthanakit T; Lumbiganon P; Hansudewechakul R; Siew Moy F; Law M; Kumarasamy N; Razali K; Sirisanthana V; Sohn AH; Chokephaibulkit K
    Pediatr Infect Dis J; 2014 Jul; 33(7):747-52. PubMed ID: 24378942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy in a thousand patients with AIDS in Haiti.
    Severe P; Leger P; Charles M; Noel F; Bonhomme G; Bois G; George E; Kenel-Pierre S; Wright PF; Gulick R; Johnson WD; Pape JW; Fitzgerald DW
    N Engl J Med; 2005 Dec; 353(22):2325-34. PubMed ID: 16319381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
    Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
    AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
    Gona P; Van Dyke RB; Williams PL; Dankner WM; Chernoff MC; Nachman SA; Seage GR
    JAMA; 2006 Jul; 296(3):292-300. PubMed ID: 16849662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa.
    Van der Borght SF; Clevenbergh P; Rijckborst H; Nsalou P; Onyia N; Lange JM; de Wit TF; Van der Loeff MF
    Antivir Ther; 2009; 14(1):63-74. PubMed ID: 19320238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort.
    Manzardo C; Esteve A; Ortega N; Podzamczer D; Murillas J; Segura F; Force L; Tural C; Vilaró J; Masabeu A; Garcia I; Guadarrama M; Ferrer E; Riera M; Navarro G; Clotet B; Gatell JM; Casabona J; Miró JM;
    Clin Microbiol Infect; 2013 Jul; 19(7):646-53. PubMed ID: 22967234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.